A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Janssen BioPharma, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03403348
- Locations
- 🇬🇧
hVIVO Services Limited, London, United Kingdom
🇬🇧Hammersmith Medicines Research Ltd, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath